| 1 | routine | 11,602 |
| 2 | compulsory | 174 |
| 3 | physician-led | 27 |
| 4 | protocolised | 16 |
| 5 | ward-based | 16 |
| 6 | in-pharmacy | 13 |
| 7 | protocol-mandated | 12 |
| 8 | preparticipation | 9 |
| 9 | non-routine | 8 |
| 10 | repeated-course | 5 |
| 11 | non-endoscopic | 4 |
| 12 | sudarshan | 4 |
| 13 | 30-night | 3 |
| 14 | covance | 3 |
| 15 | emergency-focused | 3 |
| 16 | harmonisation-good | 3 |
| 17 | 30-gy/10-fraction | 2 |
| 18 | cdc/atsdr | 2 |
| 19 | cordioprev | 2 |
| 20 | dva-subsidized | 2 |
| 21 | fractions.the | 2 |
| 22 | high-interference | 2 |
| 23 | mid-tool | 2 |
| 24 | nonindustrial | 2 |
| 25 | pgx/bm-guided | 2 |
| 26 | post-campaign | 2 |
| 27 | rehabilitation.the | 2 |
| 28 | station-based | 2 |
| 29 | study-the | 2 |
| 30 | tethersonde | 2 |
| 31 | underutilizing | 2 |
| 32 | //clinicaltrials.gov/show/nct01762501 | 1 |
| 33 | 1000-l | 1 |
| 34 | 103/863 | 1 |
| 35 | 113.6±8.8° | 1 |
| 36 | 20.607 | 1 |
| 37 | 300/8649 | 1 |
| 38 | 8,451 | 1 |
| 39 | 8-μm | 1 |
| 40 | adaptive/flexible | 1 |
| 41 | anti-uv | 1 |
| 42 | antibody-protein | 1 |
| 43 | apn-provided | 1 |
| 44 | at-point-of-care | 1 |
| 45 | bone-risk | 1 |
| 46 | cemt-pi-l. | 1 |
| 47 | concussion-associated | 1 |
| 48 | conspicous | 1 |
| 49 | cytotoxicity/genotoxicity | 1 |
| 50 | disaster-related | 1 |
| 51 | doctor-recommended | 1 |
| 52 | ebm-trained | 1 |
| 53 | ecg-independent | 1 |
| 54 | endometrial-cancer | 1 |
| 55 | estabilished | 1 |
| 56 | ewa/prosthesis | 1 |
| 57 | facx6 | 1 |
| 58 | family-sensitive | 1 |
| 59 | field-level | 1 |
| 60 | gabapentinaand | 1 |
| 61 | gestalt-based | 1 |
| 62 | giscience | 1 |
| 63 | harmonization/good | 1 |
| 64 | hsv2b | 1 |
| 65 | hypothermia-ii | 1 |
| 66 | hypoventilation-related | 1 |
| 67 | labor.in | 1 |
| 68 | later-phase | 1 |
| 69 | living.the | 1 |
| 70 | lymphome | 1 |
| 71 | mbc.relevant | 1 |
| 72 | millon | 1 |
| 73 | more-appropriate | 1 |
| 74 | multi-course | 1 |
| 75 | noise-minimized | 1 |
| 76 | non-audit | 1 |
| 77 | non-de-novo | 1 |
| 78 | non-isogenic | 1 |
| 79 | non-mmse | 1 |
| 80 | non-university-based | 1 |
| 81 | nonreplicate | 1 |
| 82 | ntr2300 | 1 |
| 83 | pre-import | 1 |
| 84 | pre-marketed | 1 |
| 85 | preneurosurgical | 1 |
| 86 | prset | 1 |
| 87 | reduced-frequency | 1 |
| 88 | reinventing | 1 |
| 89 | sapacitabine-based | 1 |
| 90 | siop-based | 1 |
| 91 | subpecialty | 1 |
| 92 | surgery.- | 1 |
| 93 | tof.this | 1 |
| 94 | wardbased | 1 |
| 95 | well-supervised | 1 |
| 96 | wide-sweeping | 1 |
| 97 | wyeth-sponsored | 1 |
| 1 | //clinicaltrials.gov/show/nct01762501 | 1 |
| 2 | 1000-l | 1 |
| 3 | 103/863 | 1 |
| 4 | 113.6±8.8° | 1 |
| 5 | 20.607 | 1 |
| 6 | 30-gy/10-fraction | 2 |
| 7 | 30-night | 3 |
| 8 | 300/8649 | 1 |
| 9 | 8,451 | 1 |
| 10 | 8-μm | 1 |
| 11 | adaptive/flexible | 1 |
| 12 | anti-uv | 1 |
| 13 | antibody-protein | 1 |
| 14 | apn-provided | 1 |
| 15 | at-point-of-care | 1 |
| 16 | bone-risk | 1 |
| 17 | cdc/atsdr | 2 |
| 18 | cemt-pi-l. | 1 |
| 19 | compulsory | 174 |
| 20 | concussion-associated | 1 |
| 21 | conspicous | 1 |
| 22 | cordioprev | 2 |
| 23 | covance | 3 |
| 24 | cytotoxicity/genotoxicity | 1 |
| 25 | disaster-related | 1 |
| 26 | doctor-recommended | 1 |
| 27 | dva-subsidized | 2 |
| 28 | ebm-trained | 1 |
| 29 | ecg-independent | 1 |
| 30 | emergency-focused | 3 |
| 31 | endometrial-cancer | 1 |
| 32 | estabilished | 1 |
| 33 | ewa/prosthesis | 1 |
| 34 | facx6 | 1 |
| 35 | family-sensitive | 1 |
| 36 | field-level | 1 |
| 37 | fractions.the | 2 |
| 38 | gabapentinaand | 1 |
| 39 | gestalt-based | 1 |
| 40 | giscience | 1 |
| 41 | harmonisation-good | 3 |
| 42 | harmonization/good | 1 |
| 43 | high-interference | 2 |
| 44 | hsv2b | 1 |
| 45 | hypothermia-ii | 1 |
| 46 | hypoventilation-related | 1 |
| 47 | in-pharmacy | 13 |
| 48 | labor.in | 1 |
| 49 | later-phase | 1 |
| 50 | living.the | 1 |
| 51 | lymphome | 1 |
| 52 | mbc.relevant | 1 |
| 53 | mid-tool | 2 |
| 54 | millon | 1 |
| 55 | more-appropriate | 1 |
| 56 | multi-course | 1 |
| 57 | noise-minimized | 1 |
| 58 | non-audit | 1 |
| 59 | non-de-novo | 1 |
| 60 | non-endoscopic | 4 |
| 61 | non-isogenic | 1 |
| 62 | non-mmse | 1 |
| 63 | non-routine | 8 |
| 64 | non-university-based | 1 |
| 65 | nonindustrial | 2 |
| 66 | nonreplicate | 1 |
| 67 | ntr2300 | 1 |
| 68 | pgx/bm-guided | 2 |
| 69 | physician-led | 27 |
| 70 | post-campaign | 2 |
| 71 | pre-import | 1 |
| 72 | pre-marketed | 1 |
| 73 | preneurosurgical | 1 |
| 74 | preparticipation | 9 |
| 75 | protocol-mandated | 12 |
| 76 | protocolised | 16 |
| 77 | prset | 1 |
| 78 | reduced-frequency | 1 |
| 79 | rehabilitation.the | 2 |
| 80 | reinventing | 1 |
| 81 | repeated-course | 5 |
| 82 | routine | 11,602 |
| 83 | sapacitabine-based | 1 |
| 84 | siop-based | 1 |
| 85 | station-based | 2 |
| 86 | study-the | 2 |
| 87 | subpecialty | 1 |
| 88 | sudarshan | 4 |
| 89 | surgery.- | 1 |
| 90 | tethersonde | 2 |
| 91 | tof.this | 1 |
| 92 | underutilizing | 2 |
| 93 | ward-based | 16 |
| 94 | wardbased | 1 |
| 95 | well-supervised | 1 |
| 96 | wide-sweeping | 1 |
| 97 | wyeth-sponsored | 1 |
| 1 | surgery.- | 1 |
| 2 | cemt-pi-l. | 1 |
| 3 | ntr2300 | 1 |
| 4 | //clinicaltrials.gov/show/nct01762501 | 1 |
| 5 | 8,451 | 1 |
| 6 | 103/863 | 1 |
| 7 | facx6 | 1 |
| 8 | 20.607 | 1 |
| 9 | 300/8649 | 1 |
| 10 | hsv2b | 1 |
| 11 | non-isogenic | 1 |
| 12 | non-endoscopic | 4 |
| 13 | pgx/bm-guided | 2 |
| 14 | apn-provided | 1 |
| 15 | doctor-recommended | 1 |
| 16 | estabilished | 1 |
| 17 | physician-led | 27 |
| 18 | ebm-trained | 1 |
| 19 | wyeth-sponsored | 1 |
| 20 | ward-based | 16 |
| 21 | sapacitabine-based | 1 |
| 22 | station-based | 2 |
| 23 | siop-based | 1 |
| 24 | gestalt-based | 1 |
| 25 | non-university-based | 1 |
| 26 | wardbased | 1 |
| 27 | protocolised | 16 |
| 28 | well-supervised | 1 |
| 29 | emergency-focused | 3 |
| 30 | protocol-mandated | 12 |
| 31 | concussion-associated | 1 |
| 32 | hypoventilation-related | 1 |
| 33 | disaster-related | 1 |
| 34 | pre-marketed | 1 |
| 35 | dva-subsidized | 2 |
| 36 | noise-minimized | 1 |
| 37 | gabapentinaand | 1 |
| 38 | harmonisation-good | 3 |
| 39 | harmonization/good | 1 |
| 40 | covance | 3 |
| 41 | giscience | 1 |
| 42 | high-interference | 2 |
| 43 | tethersonde | 2 |
| 44 | study-the | 2 |
| 45 | living.the | 1 |
| 46 | rehabilitation.the | 2 |
| 47 | fractions.the | 2 |
| 48 | adaptive/flexible | 1 |
| 49 | lymphome | 1 |
| 50 | routine | 11,602 |
| 51 | non-routine | 8 |
| 52 | at-point-of-care | 1 |
| 53 | later-phase | 1 |
| 54 | non-mmse | 1 |
| 55 | repeated-course | 5 |
| 56 | multi-course | 1 |
| 57 | nonreplicate | 1 |
| 58 | more-appropriate | 1 |
| 59 | family-sensitive | 1 |
| 60 | wide-sweeping | 1 |
| 61 | reinventing | 1 |
| 62 | underutilizing | 2 |
| 63 | hypothermia-ii | 1 |
| 64 | bone-risk | 1 |
| 65 | 1000-l | 1 |
| 66 | preneurosurgical | 1 |
| 67 | nonindustrial | 2 |
| 68 | field-level | 1 |
| 69 | mid-tool | 2 |
| 70 | 8-μm | 1 |
| 71 | sudarshan | 4 |
| 72 | post-campaign | 2 |
| 73 | labor.in | 1 |
| 74 | antibody-protein | 1 |
| 75 | preparticipation | 9 |
| 76 | 30-gy/10-fraction | 2 |
| 77 | millon | 1 |
| 78 | non-de-novo | 1 |
| 79 | cdc/atsdr | 2 |
| 80 | endometrial-cancer | 1 |
| 81 | tof.this | 1 |
| 82 | ewa/prosthesis | 1 |
| 83 | conspicous | 1 |
| 84 | prset | 1 |
| 85 | 30-night | 3 |
| 86 | non-audit | 1 |
| 87 | mbc.relevant | 1 |
| 88 | ecg-independent | 1 |
| 89 | pre-import | 1 |
| 90 | cordioprev | 2 |
| 91 | anti-uv | 1 |
| 92 | in-pharmacy | 13 |
| 93 | reduced-frequency | 1 |
| 94 | compulsory | 174 |
| 95 | cytotoxicity/genotoxicity | 1 |
| 96 | subpecialty | 1 |
| 97 | 113.6±8.8° | 1 |